AMENDED CLAIMS

1. A crystalline (3R)4-(2-methylalanyl-D-tryptophyl}-3-(phenylmethyi}-3- piperidinecarboxylic acid 1,2,2-
trimethylhydrazide. 1

2. The crystalline composition of Claim 1, wherein the crystalline composition is anhydrous.
3. The crystalline composition of Claim 1, wherein the crystalline composition is a hydrate.
4. The crystalline composition of Claim 3, wherein the hydrate is a dihydrate.

5. A crystalline (3R}4-(2-methylalanyl-D-tryptophyl)-3-(phenylmethyl)-3- piperidinecarboxylic acid 1,2,2-
trimethylhydrazide according to claim 1, having an X-ray powder diffraction pattern having 26 values
measured using Cu Ka radiation of: 10.1, 11.1, 17.6, 20.0, and 20.8.

6. А process for preparing crystalline (3R)-1-(2-methylalanyl-D-tryptophyl)-3-(phenylmethyl)-3-
piperidinecarboxylic acid 1,2,2-trimethylhydrazide as set forth in claim 4, comprising the steps of: -

a) combining (3R)-1-(2-methylalanyl-D-tryptophy|)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-
trimethylhydrazide with a solvent; wherein the solvent is selected from the group consisting of methanol
and mixtures thereof with water;

b) precipitating the crystals from the solvent; and

c) isolating the crystals.

7. The process of Claim 6, wherein the solvent is a mixture of methanol and water, and wherein the solvent
includes between 20% v/v methanol and 80 % v/v methanol.

8. The process of Claim 7, wherein the solvent includes between 40% v/v methanol and 60 % v/v methanol.

9. The process of Claims 6,7, or 8, wherein the solvent is at an elevated temperature while combining with
(3R)4-(2-methylalanyl-D-tryptophyl}-3-(phenyimethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide
in step a); or wherein the solvent is heated to an elevated temperature after combining with (3R)-1-(2-
methylalanyl-D-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide in step
a); and wherein the elevated temperature is between 65°C and 75°C.

10. The process of any one of claims 6 to 9, wherein the crystals are precipitated in step b) by cooling the
solvent.

11. The process of claim 10, wherein the solvent is cooled to ambient temperature.

12. The process of any one of claims 6 to 11, wherein the crystals are isolated in step c) by filtering the
crystals from the solvent.

13. The process of any one of claims 6 to 12, further including the step of drying the isolated crystals.

14. A pharmaceutical composition comprising the crystalline (3R)-1-(2-m ethylalanyl-D-tryptophyl)-3-
(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide of claim 4 and at least one
pharmaceutically acceptable carrier or diluent.

_ 15. Use of a therapeutically effective amount of the crystalline (3R)4-(2-methylalanyl-D- tryptophyl)-3-
(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide of claim 4 in the manufacture of a
medicament for stimulating the release of growth hormone from the pituitary of a mammal.
